Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess (Acellular Tissue Engineered Vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

HumacyteMar 3 00:00 ET

H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsFeb 28 12:31 ET · Ratings

$HUMA Stock Is up 7% Today. Here's What We See in Our Data.

Quiver QuantitativeFeb 27 10:31 ET

Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $17

Moomoo NewsFeb 27 08:35 ET · Ratings

Express News | Humacyte Issued US Patent Covering Manufacturing Of Symvess And Other Bioengineered Tissues

BenzingaFeb 27 08:01 ET

Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF) and Humacyte (HUMA)

TipRanksFeb 27 07:40 ET · Ratings